The selective delivery of antineoplastic agents to tumours is a concept which has led to the search for methods of drug targeting. One approach with chemotherapeutic drugs involves chemical modification of existing compounds to form prodrugs which although pharmacologically inert can be converted to active agents at tumour sites (Stella et al., 1980) . Generally, this approach is limited, however, we have recently incorporated this 'prodrug' concept into an alternative approach which uses monoclonal antibodies (MoAbs) to specifically target drugs to tumours (Smyth et al., 1986a) . By covalently conjugating an inactive N-acetyl derivative of melphalan (N-AcMel) ('prodrug') to MoAbs involved in endocytotic pathways (Smyth et al., 1986b) , tumour specific conjugates were produced which were cytotoxic following internalisation and lysosomal degradation within the target tumour cell. These N-AcMELMoAb conjugates displayed in vitro and in vivho specificity and cytotoxicity (Smyth et at., 1986a) however, in an attempt to improve results in vivo we now report on the coupling of F(ab'), fragments to N-AcMEL. The use of F(ab'), fragments should have several advantages; firstly the nonspecific binding to non-tumour cells via Fc receptors would be avoided; secondly the Fc portion is the most immunogenic portion of the MoAb so that if the use of murine MoAbs is contemplated for therapy, then the less immunogenic F(ab')2 preparation could be desirable. Finally the removal of the Fc portion of the MoAb decreases its molecular size by approx. 30%, which has been considered to permit conjugates to more efficiently permeate the physiological barriers and avoid cellular barriers (reticuloendothelial system) when passing from the circulation to a tumour (Poznansky et al., 1984) . Subsequently we investigated and compared the in vitro and in vivo efficacy of F(ab')2 conjugates with conjugates of N-AcMEL and intact IgG MoAb.
Materials and methods
Tumi?our cells E3, a clonal variant of the murine thymoma ITT(1)75NS (Smyth et al., 1986c) ; and the murine lymphoma EL4 (Horowitz Ct al., 1968) 
Monoclonal antibodty
The anti-Ly-2.1 MoAb (IgGl) (Hogarth et at., 1982) was isolated from ascitic fluid by precipitation with 40% ammonium sulphate, and the IgG fraction was adsorbed onto Protein A Sepharose (Pharmacia, Piscataway, NJ), washed extensively with PBS (pH 7.3) and eluted with 0.2 M glycine/HC1 (pH 2.8). Following neutralisation, the MoAb was dialysed against PBS, aliquoted and stored at -70 C. The antibody activity was determined by rosetting with sheep anti-mouse immunoglobulin (SAMG) (Parish et al., 1978) .
Preparation of F(ab')2 by pepsin degradation1
The optimal conditions of degradation adopted for preparation of F(ab')2 fragments of the anti-Ly-2.1 MoAb were 0.1 M citrate, pH3.8, at 37 C for 6-8h using IgG concentrations of 1 to 2 mg ml1 and pepsin concentrations of 25 pg ml- (Parham, 1983) . Intact IgG was removed using Protein A-Sepharose (Pharmacia) and each preparation was calculated for yield (> 80%) and characterized by polyacrylamide gel electrophoresis under reducing and nonreducing conditions. Prepar-ation of N-AcMEL-IgG and N-AcMEL-F(ab')2 conjugates An N-acetyl derivative of MEL was prepared and conjugated to whole IgG and F(ab')2 as described (Smyth et al., 1986a) . Briefly, MEL was acetylated using acetic anhydride and an active ester of this N-AcMEL derivative was then coupled to the amino groups of the MoAb. M.J. SMYTH ct at.
Antiodly (aCtilviti' A rosetting assay (Parish et al., 1978) has previously demonstrated the antibody activity of N-AcMEL-IgG conjugates (Smyth et at., 1986a were collected in sterile plastic centrifuge tubes, resuspended in sterile drug or F(ab')2 conjugate and mixed for 30min at 37 C. The cells were centrifuged (400gx5min) and then resuspended in growth medium; 1001,l of cells were then seeded into a microtitre plate using duplicate wells/sample and incubated for 16-24h . After the incubation period in both assays, 50ul of medium containing 1 lCi of [3H]-thymidine (specific activity-5Cimmol-1; Amersham) was added and the plates incubated for 2-4 h; cells were then harvested; dried for 0 min at 80 C and samples counted on a scintillation counter. Incorporation of [3H]-thymidine was expressed as a percentage inhibition in incorporation of controls. Standard error for any given point was generated by duplicate determinations and did not exceed 5% for any given experimental point.
In vivo experiments
Tumiiour growtth Tumour cells were injected s.c. into the abdominal wall and were allowed to develop into palpable tumours before commencing treatment. Mice were then subjected to a series of i.v. treatments and the size of the tumours measured daily with a caliper square measuring along the perpendicular axes of the tumours; the data were recorded as the mean tumour size (product of two diameters+s.e.). Experimental groups of 8-10 mice, all of the same sex and age were used in each experiment.
Results
These studies were designed to demonstrate that N-AcMEL could be covalently coupled to F(ab')2 fragments of MoAbs whilst maintaining drug and antibody activity in vitro and to compare these conjugates with N-AcMEL covalently bound to IgG MoAb in solid tumour models.
Coupling of N-AcMEL to F(ab')2 The anti-Ly-2.1 F(ab')2 was reacted with different amounts of N-AcMEL active ester to produce conjugates which varied in the amount of drug coupled. It was found that the addition of 230nmol of N-AcMEL active ester to 5 nmole of F(ab')2 led to an incorporation of 6 molecules of N-AcMEL per molecule F(ab')2 with a 85% recovery of protein ( Figure  1 
C0totoxicitv in vitro
The cytotoxicity of the anti-Ly-2. I F(ab')2 conjugate was It was necessary to show that the inhibitory activity of NAcMEL F(ab'), conjugates was specific for target cells reactive with the MoAb as previously described for NAcM EL-IgG conjugates (Smyth et a!l., 1986ca tration of 1.5 x 10M compared with 1.5x10 M for free N-AcMEL. By contrast EL4 (Ly-2 -) which was 10 times more sensitive to free N-AcMEL than E3 was relatively resistant to the cytotoxic effect of the F(ab'), (Ly-2+) conjugate over the molar concentration range tested. There was inhibition of tumour growth in mice which received either N-AcMEL conjugate, compared to those receiving PBS, N-AcMEL or antibody alone ( Figure 5 ). By day 6 the conjugate groups had smaller tumours than either the N-AcMEL or F(ab')2 treated mice and by day 11 the mean tumour size of N-AcMEL-IgG treated mice was 50% that of PBS treated mice. (Smyth et al., 1986a) or N-AcMEL-anti-Ly-2.1 F(ab'), conjugate. The amount of N-AcMEL or MEL administered was 8,g on day 3, 15 pg on day 5 and 7 pg on day 6 (i.e. total 30 pg N-AcMEL). As previously noted, those mice receiving N-AcMEL and anti-Ly-2.1 in their treatments had smaller tumours than those receiving PBS, MEL or antibody alone (Figure 6 ) just seven days after tumour inoculation and by day 11 the mean tumour size of F(ab')2 conjugate treated mice was 15% that of PBS treated mice and 20% that of N-AcMEL-anti-TFR treated mice. The individual tumour growth curves of F(ab')2 conjugate treated mice revealed that 9/10 of the mice demonstrated a reduction in tumour size during the treatment period (days 5-6), 5 of these tumours completely regressing and not redeveloping (Figure 7) . At the termination of F(ab')2 conjugate treatment the remaining 4 tumours began to increase in size, growing at variable rates all slower than the mean growth rate of PBS treated mice. It is also clear that one of the mice only demonstrated a minor response to the F(ab')2 conjugate. In an additional group of mice treated identically with NAcMEL-IgG (anti-Ly-2.1) conjugate 4/10 of the tumours were completely eradicated (data not shown). To reduce the non-specific toxicity of MEL, a less cytotoxic N-AcMEL derivative was synthesised and coupled to MoAbs (Smyth et al., 1986a) . This N-AcMEL-IgG conjugate was demonstrated to enter cells via the MoAb not the phenylalanine amino acid transport system and therefore was only cytotoxic to cells which bound the MoAb. In addition N-AcMEL-IgG conjugates more effectively eradicated tumours in vivo than free MEL, N-AcMEL or antibody alone, being most efficacious when administered i.v. (Smyth et al., 1986a) . In this study we have attempted to further increase the specificity and cytotoxicity of N-AcMEL-IgG conjugates by cleaving the Fc portion of the MoAb and coupling the derived F(ab')2 fragment to N-AcMEL. Using the same conjugation procedure as for N-AcMEL-IgG conjugates (Smyth et al., 1986a) , the N-AcMEL active ester was successfully coupled to F(ab')2 fragments and conjugates with up to 20 molecules of N-AcMEL bound per molecule F(ab'), were produced (Figure 1 ). In addition to retaining its F(ab'), activity (Figure 2 ), the F(ab')2 conjugate was shown to retain the cytotoxic effect of N-AcMEL, increasing the anti-tumour activity of bound N-AcMEL to 50 times that of an equimolar amount of free N-AcMEL (Figure 3 ). The F(ab')2 conjugate also exhibited specificity to target cells in cytotoxicity assays performed in vitro (Figure 4 ). The F(ab')2 binding activity of the conjugate clearly resulted in the conjugates selective cytotoxicity, as the F(ab')2 conjugate displayed cytotoxicity only to Ly-2+ E3 cells being more cytotoxic than N-AcMEL alone. These in vitro studies were performed to ascertain whether the F(ab')2 fragments could be covalently coupled to NAcMEL with retention of the conjugate's specificity and cytotoxicity. The conjugation of F(ab')2 fragments of antiLy-2.1 to N-AcMEL has been demonstrated to be comparable to the conjugation of whole anti-Ly-2.1 and NAcMEL, except that fewer N-AcMEL molecules can be bound to F(ab')2 whilst retaining antibody activity, protein solubility and recovery. Not surprisingly therefore, the F(ab')2 conjugate was as cytotoxic as the intact IgG conjugate in vitro.
Once the cytotoxic activity of the F(ab')2 conjugate had been established in vitro, the in vivo efficacy of the F(ab'), conjugate was investigated using established solid tumour models. In the first s.c. tumour growth experiment, therapy did not commence until palpable lumps were established and of the i.v. treatments administered the F(ab')2 conjugate was the most effective tumour inhibitor ( Figure 5 ). Its effect was only marginally superior to N-AcMEL-IgG treatment and of all the F(ab')2 conjugate treated mice that demonstrated a reduction in tumour size (6/10) only two mice had tumours that completely regressed, these too redeveloping 6 days after the completion of treatment. In order to assess the limitation of conjugate therapy considering the promising anti-tumour activity of i.v. conjugate treatment in individual mice, we injected CBF1 mice s.c. with 2.0 x 106 cells and began i.v. treatments one day prior to solid tumour development. Although in this and the initial tumour growth experiment, conjugate treated mice received 30,ug of N-AcMEL, a greater reduction in tumour size was achieved with earlier treatment. Individual tumour growth curves demonstrated that 9/10 of the tumours reduced in size during the course of treatment ( Figure 7 ) and five of these tumours regressed and did not reappear (>200 days), a result which represents our first successful i.v. cure of s.c. implanted ITT(1)75NS E3 tumours using the i.v. route of administration. Earlier i.v. treatment of mice with 30,ug of N-AcMEL-lgG was almost as effective as F(ab')2 conjugate treatment and thus by varying tumour cell number and treatment schedule in two tumour growth experiments we have been unable to demonstrate a major difference in the in vivo efficacy of the N-AcMEL-IgG conjugate and the F(ab')2 conjugate. An important feature of F(ab')2 fragments is their inability to bind Fc receptors on macrophages and hepatocytes which should therefore limit conjugate accumulation in the liver and the reticuloendothelial system and on account of their smaller size, F(ab')2 conjugates should also be capable of penetrating the capillary network of the tumour. In contrast however, the shorter half life (faster clearance) and generally lower affinity of F(ab')2 fragments may result in a lower concentration of F(ab')2 conjugate in the tumour than is possible with intact IgG conjugate (Wahl ct al., 1983) . In this case it remains unclear, which of these properties of MoAbs is the most important when delivering cytotoxic drugs to tumours.
Additionally, it is evident that kinetics of MoAb uptake, the relationship between tumour size and MoAb binding and the site of MoAb deposition are valuable criteria in determining the relative effectiveness of F(ab')2 and intact MoAb-drug conjugates. Consequently, the possibility of using F(ab')2 conjugates therapeutically will depend on giving doses high enough to compensate for their rapid clearance from the tumour site.
